文献速递产科母胎医学

无创DNA筛查女性中超声的作用

The role of ultrasound in women who undergo cell-free DNA screening.
PubMed 文献 · Am J Obstet Gynecol · 2017-01-17

本文回顾无创DNA筛查女性中超声作用的现有数据,由母胎医学会提出6条推荐。已获阴性无创DNA筛查者不推荐仅因颈项透明层测量而行11-14周超声(1B级);孤立软指标且无创DNA阴性时不推荐诊断性检测(2B级),该软指标应描述为无临床意义或正常变异(2B级);发现结构异常应提供染色体微阵列诊断检测(1A级);不推荐常规无创DNA筛查微缺失(1B级)。

要点

  • 无创DNA筛查阴性者,不推荐仅因颈项透明层测量在11-14周行超声(1B级)。
  • 孤立软指标且无创DNA阴性时,不推荐诊断性检测(2B级),应描述为无临床意义或正常变异(2B级)。
  • 超声发现结构异常时,应提供染色体微阵列诊断检测(1A级);不推荐常规无创DNA筛查微缺失(1B级)。

核心结论

  • 已获阴性无创DNA筛查者不推荐仅因颈项透明层测量行11-14周超声(1B级);孤立软指标且无创DNA阴性时不推荐诊断性检测(2B级);发现结构异常应提供染色体微阵列诊断检测(1A级);不推荐常规无创DNA筛查微缺失(1B级)。

研究设计与样本

  • 本文为母胎医学会文件,回顾无创DNA筛查女性中超声作用的现有数据。

主要发现

  • 已获阴性无创DNA筛查者,仅因颈项透明层测量行11-14周超声不推荐(1B级)。
  • 孤立软指标且无创DNA阴性时,不推荐诊断性检测(2B级),该软指标应描述为无临床意义或正常变异(2B级)。
  • 孤立软指标且无其他临床意义(如脉络丛囊肿或心内强回声灶)且孕早期或孕中期筛查阴性时,建议描述为无临床意义或正常变异(2B级)。

关键数值与推荐

  • 推荐1:已获阴性无创DNA筛查者,不推荐仅因颈项透明层测量行11-14周超声(1B级)。
  • 推荐2:孤立软指标且无创DNA阴性时,不推荐诊断性检测(2B级)。
  • 推荐3:孤立软指标无其他临床意义(如脉络丛囊肿或心内强回声灶)且无创DNA阴性时,建议描述为无临床意义或正常变异(2B级)。
  • 推荐4:孤立软指标无其他临床意义且孕早期或孕中期筛查阴性时,建议描述为无临床意义或正常变异(2B级)。
  • 推荐5:超声发现结构异常者,应提供染色体微阵列诊断检测(1A级)。

临床怎么用

  • 已获阴性无创DNA筛查者,不推荐仅因颈项透明层测量行11-14周超声(1B级)。
  • 孤立软指标且无创DNA阴性时,不推荐诊断性检测(2B级),建议描述为无临床意义或正常变异(2B级)。
  • 超声发现结构异常时,应提供染色体微阵列诊断检测(1A级)。
  • 不推荐常规无创DNA筛查微缺失(1B级)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of cell-free DNA screening for aneuploidy into obstetric practice in 2011 revolutionized the strategies utilized for prenatal testing. The purpose of this document is to review the current data on the role of ultrasound in women who have undergone or are considering cell-free DNA screening. The following are Society for Maternal-Fetal Medicine recommendations: (1) in women who have already received a negative cell-free DNA screening screen, ultrasound at 11-14 weeks of gestation solely for the purpose of nuchal translucency measurement (Current Procedural Terminology code 76813) is not recommended (grade 1B); (2) we recommend that diagnostic testing should not be recommended to patients solely for the indication of an isolated soft marker in the setting of a negative cell-free DNA screen (grade 2B); (3) in women with an isolated soft marker without other clinical implications (ie, choroid plexus cyst or echogenic intracardiac focus) and a negative cell-free DNA screen, we recommend describing the finding as not clinically significant or as a normal variant (grade 2B); (4) in women with an isolated soft marker that has no other clinical implication (ie, choroid plexus cyst or echogenic intracardiac focus) and a negative first- or second-trimester screening result, we recommend describing the finding as not clinically significant or as a normal variant (grade 2B); (5) we recommend that all women in whom a structural abnormality is identified by ultrasound should be offered diagnostic testing with chromosomal microarray (grade 1A); and (6) we recommend against routine screening for microdeletions with cell-free DNA screening (grade 1B).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Norton ME, Biggio JR, Kuller JA, et al. The role of ultrasound in women who undergo cell-free DNA screening. Am J Obstet Gynecol. 2017. PMID: 28108156. doi:10.1016/j.ajog.2017.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。